Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Hydroxychloroquine: Adverse Drug Reaction Profile of an Old Drug in a New Situation

Author(s): Deepti Chopra, Bharti Bhandari*, Jayant Rai, Rashmi Upadhyay, Jaspreet Kaur Sidhu and Saurabh Srivastava

Volume 17, Issue 4, 2022

Published on: 29 April, 2022

Page: [370 - 374] Pages: 5

DOI: 10.2174/1574886317666220301111913

Price: $65

Abstract

Background: Hydroxychloroquine (HCQ) has been extensively used during the COVID-19 pandemic both as a therapeutic and prophylactic drug. HCQ is generally well tolerated; however, adverse drug reactions (ADRs) in COVID-19 need further exploration. In this study, we have determined the type and pattern of ADRs of HCQ as a prophylactic and therapeutic drug in COVID-19.

Methods: All spontaneous suspected ADR reports due to HCQ in COVID-19 patients submitted to the ADR monitoring of a tertiary care hospital were included. Additionally, a survey was designed for active surveillance of ADRs among healthcare professionals (HCPs) who were on prophylaxis with HCQ. The ADRs were analyzed to determine severity, causality, and preventability using the Hartwig Scale, World Health Organisation-Uppasala Monitoring Centre (WHO–UMC) scale, and modified Schumock and Thornton criterion respectively.

Results: Sixty-four ADR reports were received from COVID-19 patients. A total of 78 ADRs were reported by 49 HCPs who were on HCQ prophylaxis. The majority of the patients had ADRs related to skin and soft tissues (37.5%), whereas the HCPs on prophylaxis mostly had gastrointestinal complaints (42.3%). ADRs observed in HCPs on prophylaxis were mild, not requiring any intervention. However, 50% of ADRs in patients were of “moderate” category.

Conclusion: Undiscerning and unsupervised use of HCQ can expose the general population as well as patients to serious adverse drug effects. Utmost care is necessary before using HCQ prophylactically or for treatment in COVID-19.

Keywords: COVID-19, ADRs, hydroxychloroquine, prophylaxis, HCQ, healthcare professionals.

« Previous Next »
Graphical Abstract

[1]
Chandel V, Raj S, Rathi B, Kumar D. In silico identification of potent COVID-19 main protease inhibitors from FDA approved antiviral compounds and active phytochemicals through molecular docking: A drug repurposing approach. 2020; Preprints 2020030349.
[2]
Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y. Hydroxychloroquine: From malaria to autoimmunity. Clin Rev Allergy Immunol 2012; 42(2): 145-53.
[http://dx.doi.org/10.1007/s12016-010-8243-x] [PMID: 21221847]
[3]
Zhuang MW, Cheng Y, Zhang J, et al. Increasing host cellular receptor-angiotensin-converting enzyme 2 expression by coronavirus may facilitate 2019-nCoV (or SARS-CoV-2) infection. J Med Virol 2020; 92(11): 2693-701.
[http://dx.doi.org/10.1002/jmv.26139] [PMID: 32497323]
[4]
Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579(7798): 270-3.
[http://dx.doi.org/10.1038/s41586-020-2012-7] [PMID: 32015507]
[5]
Devaux CA, Rolain J-M, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: What to expect for COVID-19? Int J Antimicrob Agents 2020; 105938.
[6]
Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: An old drug against today’s diseases? Lancet Infect Dis 2003; 3(11): 722-7.
[http://dx.doi.org/10.1016/S1473-3099(03)00806-5] [PMID: 14592603]
[7]
Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med 2020; 382(24): 2372-4.
[http://dx.doi.org/10.1056/NEJMc2010419] [PMID: 32302078]
[8]
Plantone D, Koudriavtseva T. Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neu-rological diseases: A mini-review. Clin Drug Investig 2018; 38: 653.
[http://dx.doi.org/10.1007/s40261-018-0656-y]
[9]
The use of the WHO–UMC system for standardised case causality assessment. Available from: www.who-umc.org/graphics/4409.pdf
[10]
Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992; 49(9): 2229-32.
[http://dx.doi.org/10.1093/ajhp/49.9.2229] [PMID: 1524068]
[11]
Lau PM, Stewart K, Dooley M. The ten most common Adverse Drug Reactions (ADRs) in oncology patients: do they matter to you? Support Care Cancer 2004; 12(9): 626-33.
[http://dx.doi.org/10.1007/s00520-004-0622-5] [PMID: 15064936]
[12]
Lenzer J. Covid-19: US gives emergency approval to hydroxychloroquine despite lack of evidence. BMJ 2020; 369: m1335.
[http://dx.doi.org/10.1136/bmj.m1335] [PMID: 32238355]
[13]
Revised advisory on the use of Hydroxychloroquine (HCQ) as prophylaxis for SARS-CoV-2 infection (in supersession of previous advisory) 2020; 10: 2020. Available from: https://www.mohfw.gov.in
[14]
Roustit M, Guilhaumou R, Molimard M, Drici MD, Laporte S, Montastruc JL. Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence. Therapie 2020; 75(4): 363-70.
[http://dx.doi.org/10.1016/j.therap.2020.05.010] [PMID: 32473812]
[15]
Montastruc JL, Rousseau V, Durrieu G, Bagheri H. Serious adverse drug reactions with hydroxychloroquine: A pharmacovigilance study in Vigibase®. Eur J Clin Pharmacol 2020; 76(10): 1479-80.
[http://dx.doi.org/10.1007/s00228-020-02920-1] [PMID: 32506216]
[16]
Nagaraja BS, Ramesh KN, Dhar D, et al. HyPE study: Hydroxychloroquine prophylaxis-related adverse events’ analysis among healthcare workers during COVID-19 pandemic: A rising public health concern. J Public Health (Oxf) 2020; 42(3): 493-503.
[http://dx.doi.org/10.1093/pubmed/fdaa074] [PMID: 32490532]
[17]
Faruqui AR, Xavier D, Kamat SK, et al. Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis. Indian J Med Res 2021; 153(1 & 2): 219-26.
[PMID: 33818480]
[18]
Kulkarni RK, Kinikar AA, Jadhav T. Adverse drug reaction profile of prophylactic hydroxychloroquine for COVID-19 among doctors. Med J DY PatilVidyapeeth 2020; 13: 204-7.
[http://dx.doi.org/10.4103/mjdrdypu.mjdrdypu_220_20]
[19]
Lofgren SMM, Nicol MR, Bangdiwala AS, et al. Safety of Hydroxychloroquine among outpatient clinical trial participants for COVID-19. Open Forum Infect Dis 2020; 7(11): ofaa500.
[http://dx.doi.org/10.1101/2020.07.16.20155531]
[20]
Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine reti-nopathy (2016 revision). Ophthalmology 2016; 123(6): 1386-94.
[http://dx.doi.org/10.1016/j.ophtha.2016.01.058] [PMID: 26992838]
[21]
Bookshelf NCBI. Drug information on hydroxychloroquine. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury Available from: https://www.ncbi.nlm.nih.gov/books/NBK548738/

Rights & Permissions Print Cite
Article Metrics
17
1
© 2024 Bentham Science Publishers | Privacy Policy